Ali Bin Abdul Jabbar, Mahmoud Ismayl, Mason Klisares, John Osborne, Mohamed Azouz, Hyo Jung Tak, Ahmed Aboeata, Amjad Kabach, Andrew M Goldsweig
{"title":"Declining myocardial infarction mortality in young and middle-aged Americans and impact of COVID-19 pandemic.","authors":"Ali Bin Abdul Jabbar, Mahmoud Ismayl, Mason Klisares, John Osborne, Mohamed Azouz, Hyo Jung Tak, Ahmed Aboeata, Amjad Kabach, Andrew M Goldsweig","doi":"10.1016/j.carrev.2025.08.021","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acute myocardial infarction (AMI) is a leading cause of cardiovascular disease (CVD) mortality among young and middle-aged individuals in the United States (US). Though AMI mortality overall has been decreasing in the US, contemporary trends in AMI-related mortality in the young and middle-aged population and the impact of the COVID-19 pandemic on these trends are unknown.</p><p><strong>Methods: </strong>The Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database was used to analyze death certificates from 1999 to 2023 for AMI-related deaths among the US population aged 25-64. Age-adjusted mortality rates (AAMRs) per 100,000 people and associated annual percent changes (APCs) were calculated using Joinpoint regression analysis. Mortality trends were stratified by sex, race/ethnicity, census region, and state for comparative analysis.</p><p><strong>Results: </strong>From 1999 to 2023, there were 970,454 AMI-related deaths among U.S. adults aged 25-64 years. The annual number of AMI-related deaths decreased from 44,040 in 1999 to 31,522 in 2023. The overall AAMR per 100,000 decreased from 31.02 deaths (95 % confidence interval [CI] 30.73-31.31) in 1999 to 15.29 (95 % CI 15.11-15.46) in 2023 (average APC -2.92 %, 95 % CI -3.22 to -2.75). The AAMR per 100,000 declined at a faster rate from 31.02 in 1999 to 19.57 in 2010 (1999-2010, APC -4.26), followed by a slower rate from 19.57 in 2010 to 16.67 in 2019 (2010-2019, APC -1.41). The declining trend was disrupted by a transient increase during the COVID-19 pandemic, with a peak AAMR of 19.73 (95 % CI, 19.53 to 19.93) in 2021 (2019-2021, APC 8.52). The declining trend resumed from 2021 to 2023, with AAMR decreasing to its lowest levels of 15.29 in 2023 (2021-2023, APC -12.58). Heterogeneity across demographic and regional groups narrowed during these 25 years. However, disparities are still prevalent, with men, non-Hispanic (NH) Black or African American, American Indian or Alaska Native, and residents of the Southern United States having higher mortality rates.</p><p><strong>Conclusion: </strong>AMI-related mortality declined significantly from 1999 through 2023 in the young and middle-aged population of the US. AMI-related mortality rates increased transiently during the COVID-19 pandemic, but the declining trend resumed in 2022. Differences across demographic and regional subgroups narrowed; however, disparities remain prevalent and require comprehensive efforts to improve cardiovascular health, outcomes, and health equity among the young and middle-aged populations of the US.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.carrev.2025.08.021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Acute myocardial infarction (AMI) is a leading cause of cardiovascular disease (CVD) mortality among young and middle-aged individuals in the United States (US). Though AMI mortality overall has been decreasing in the US, contemporary trends in AMI-related mortality in the young and middle-aged population and the impact of the COVID-19 pandemic on these trends are unknown.
Methods: The Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database was used to analyze death certificates from 1999 to 2023 for AMI-related deaths among the US population aged 25-64. Age-adjusted mortality rates (AAMRs) per 100,000 people and associated annual percent changes (APCs) were calculated using Joinpoint regression analysis. Mortality trends were stratified by sex, race/ethnicity, census region, and state for comparative analysis.
Results: From 1999 to 2023, there were 970,454 AMI-related deaths among U.S. adults aged 25-64 years. The annual number of AMI-related deaths decreased from 44,040 in 1999 to 31,522 in 2023. The overall AAMR per 100,000 decreased from 31.02 deaths (95 % confidence interval [CI] 30.73-31.31) in 1999 to 15.29 (95 % CI 15.11-15.46) in 2023 (average APC -2.92 %, 95 % CI -3.22 to -2.75). The AAMR per 100,000 declined at a faster rate from 31.02 in 1999 to 19.57 in 2010 (1999-2010, APC -4.26), followed by a slower rate from 19.57 in 2010 to 16.67 in 2019 (2010-2019, APC -1.41). The declining trend was disrupted by a transient increase during the COVID-19 pandemic, with a peak AAMR of 19.73 (95 % CI, 19.53 to 19.93) in 2021 (2019-2021, APC 8.52). The declining trend resumed from 2021 to 2023, with AAMR decreasing to its lowest levels of 15.29 in 2023 (2021-2023, APC -12.58). Heterogeneity across demographic and regional groups narrowed during these 25 years. However, disparities are still prevalent, with men, non-Hispanic (NH) Black or African American, American Indian or Alaska Native, and residents of the Southern United States having higher mortality rates.
Conclusion: AMI-related mortality declined significantly from 1999 through 2023 in the young and middle-aged population of the US. AMI-related mortality rates increased transiently during the COVID-19 pandemic, but the declining trend resumed in 2022. Differences across demographic and regional subgroups narrowed; however, disparities remain prevalent and require comprehensive efforts to improve cardiovascular health, outcomes, and health equity among the young and middle-aged populations of the US.
期刊介绍：
Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. Cardiovascular Revascularization Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell therapy, pharmacological interventions, restenosis management, and prevention, including experiments conducted in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
